Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation ...

DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting pre-clinical data on DA-1241, a ...

Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About ...

It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The ...

A Lancaster County science fair champion has earned international honors for developing a fishing lure that won’t contribute ...

The poster presented at the meeting will be made available on the Glucotrack website following the conference.

A Lancaster County science fair champion has earned international honors for developing a fishing lure that won’t contribute ...

Drawing on data from the organization's Registry of more than 20,000 people with T1D, several presentations offer insights into clinical outcomes as well as the broader impact of the disease ...